The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy
Open accessAbstract
UNLABELLED: Preliminary in vitro and in vivo studies with valproic acid (VPA) in cell lines and patients with spinal muscular atrophy (SMA) demonstrate increased expression of SMN, supporting the possibility of therapeutic benefit. We performed an open label trial of VPA in 42 subjects with SMA to assess safety and explore potential outcome measures to help guide design of future controlled clinical trials. Subjects included 2 SMA type I ages 2-3 years, 29 SMA type II ages 2-14 years and 11 type III ages 2-31 years, recruited from a natural history study. VPA was well-tolerated and without evident hepatotoxicity. Carnitine depletion was frequent and temporally associated with increased weakness in two subjects. Exploratory outcome measures included assessment of gross motor function via the modified Hammersmith Functional Motor Scale (MHFMS), electrophysiologic measures of innervation including maximum ulnar compound muscle action potential (CMAP) amplitudes and motor unit number estimation (MUNE), body composition and bone density via dual-energy X-ray absorptiometry (DEXA), and quantitative blood SMN mRNA levels. Clear decline in motor function occurred in several subjects in association with weight gain; mean fat mass increased without a corresponding increase in lean mass. We observed an increased mean score on the MHFMS scale in 27 subjects with SMA type II (p<or=0.001); however, significant improvement was almost entirely restricted to participants <5 years of age. Full length SMN levels were unchanged and Delta7SMN levels were significantly reduced for 2 of 3 treatment visits. In contrast, bone mineral density (p<or=0.0036) and maximum ulnar CMAP scores (p
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brichta, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg256 · Cited by 382
Cited by
Mercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E. S., Vitale, M., Snyder, B., Quijano-Roy, S., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.11.005 · Cited by 1,055
Self-citationKolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Self-citationD'Amico, A., Mercuri, E., Tiziano, F. D., & Bertini, E. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-71 · Cited by 577
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
Metadata
- Authors
- Swoboda, K. J., Scott, C. B., Reyna, S. P., Prior, T. W., LaSalle, B., Sorenson, S. L., Wood, J., Acsadi, G., Crawford, T. O., Kissel, J. T., Krosschell, K. J., D'Anjou, G., Bromberg, M. B., Schroth, M. K., Chan, G. M., Elsheikh, B., & Simard, L. R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-05-14
- Volume
- 4
- Issue
- 5
- Pages
- e5268
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2062270769
- Cited by
- 176
- References
- 1
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy. https://app.cochat.ai/papers/10.1371/journal.pone.0005268
- The paper
- Swoboda, K. J., Scott, C. B., Reyna, S. P., Prior, T. W., LaSalle, B., Sorenson, S. L., Wood, J., Acsadi, G., Crawford, T. O., Kissel, J. T., Krosschell, K. J., D'Anjou, G., Bromberg, M. B., Schroth, M. K., Chan, G. M., Elsheikh, B., & Simard, L. R. (2009). Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy. PLoS ONE. https://doi.org/10.1371/journal.pone.0005268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.